Pharmacodynamic aspects of sustained release preparations

被引:76
作者
Hoffman, A [1 ]
机构
[1] Hebrew Univ Jerusalem, Sch Pharm, Fac Med, Dept Pharmaceut, IL-91120 Jerusalem, Israel
关键词
pharmacodynamics; pharmacokinetics; administration rate; drug delivery; sustained release; pharmacologic response; exposure time; adverse effect; drug development;
D O I
10.1016/S0169-409X(98)00027-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The sustained release (SR) mode of drug administration has certain features that have an important impact on the magnitude of the pharmacologic response: (a) it minimizes fluctuation in blood drug concentrations (i.e. between peak and trough). However, due to the pronounced non-linear relationship between drug concentration and pharmacologic effect (i.e. pharmacodynamics) the impact of this property differs considerably as a function of the shape of the pharmacodynamic profile and the position of the specific range of concentrations on the curve of this profile; (b) it produces a slow input rate which tends to minimize the body's counteraction to the drug's intervening effect on regulated physiological processes; and (c) it provides a continuous mode of drug administration. This important pharmacodynamic characteristic may produce, in certain cases, an opposite clinical effect than that attained by an intermittent (pulsatile) mode of administration of the same drug. For many drugs with non-concentration-dependent pharmacodynamics, the exposure time, rather than the AUG, is the relevant parameter and it can therefore be optimized by SR preparations. The slow input function may minimize hysteresis in cases where the site of action is not in a rapid equilibrium with the blood circulation. The pharmacodynamics of the desired effect(s) and/or adverse effect(s) may also be influenced by the site of administration, especially in cases where the drug is delivered directly to its site of action. These factors demonstrate the important influence of the mode of administration on the pharmacological and clinical outcomes. In addition, they highlight the need to include these pharmacodynamic considerations in all stages from drug development to the optimization of their clinical use. (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:185 / 199
页数:15
相关论文
共 68 条
[1]  
ABERNETHY DR, 1988, PHARMACOKINETICS PHA, V2, P60
[2]   NOVEL DRUG DELIVERY SYSTEMS - AN OVERVIEW OF THEIR IMPACT ON CLINICAL PHARMACOKINETIC STUDIES [J].
BANERJEE, PS ;
ROBINSON, JR .
CLINICAL PHARMACOKINETICS, 1991, 20 (01) :1-14
[3]   PHARMACOKINETIC AND PHARMACODYNAMIC BASIS FOR PEPTIDE DRUG DELIVERY SYSTEM-DESIGN [J].
BREIMER, DD .
JOURNAL OF CONTROLLED RELEASE, 1992, 21 (1-3) :5-10
[4]  
BREIMER DD, 1987, PULSATILE DRUG DELIV, V33, P25
[5]   INFLUENCE OF DRUG FORMULATION ON DRUG CONCENTRATION-EFFECT RELATIONSHIPS [J].
CASTANEDAHERNANDEZ, G ;
CAILLE, G ;
DUSOUICH, P .
CLINICAL PHARMACOKINETICS, 1994, 26 (02) :135-143
[6]   CONTINUOUS INFUSION OF BETA-LACTAM ANTIBIOTICS [J].
CRAIG, WA ;
EBERT, SC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (12) :2577-2583
[7]  
Craig WA, 1986, ANTIBIOTICS LABORATO, P515
[8]   Pharmacokinetics of gentamicin at traditional versus high doses: Implications for once-daily aminoglycoside dosing [J].
Demczar, DJ ;
Nafziger, AN ;
Bertino, JS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (05) :1115-1119
[9]  
Derendorf H., 1995, Handbook of pharmacokinetic/pharmacodynamic correlation
[10]  
DOUGHERTY P M, 1988, Brain Behavior and Immunity, V2, P242, DOI 10.1016/0889-1591(88)90026-8